Cargando…

Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice

This article provides an updated review of the pharmacological profile and available efficacy and tolerability/safety data for vilazodone, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vilazodone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chauhan, Mohit, Parry, Rebecca, Bobo, William V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206504/ https://www.ncbi.nlm.nih.gov/pubmed/35726313 http://dx.doi.org/10.2147/NDT.S279342

Ejemplares similares

Vilazodone for the Treatment of Depression: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder
por: Sahli, Zeyad T., et al.
Publicado: (2016)

A Review of Vilazodone, Serotonin, and Major Depressive Disorder
por: Pierz, Kerri A., et al.
Publicado: (2014)

Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2014)

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
por: Zhang, Xiao-Fei, et al.
Publicado: (2015)

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
por: Singh, Mandeep, et al.
Publicado: (2012)

Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression
por: Khan, Arif, et al.
Publicado: (2014)

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
por: Wang, Sheng-Min, et al.
Publicado: (2015)

Clinical Relevance of Vilazodone Treatment in Patients With Major Depressive Disorder: Categorical Improvement in Symptoms
por: Culpepper, Larry, et al.
Publicado: (2014)

Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy
por: Hellerstein, David J, et al.
Publicado: (2015)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
por: Durgam, Suresh, et al.
Publicado: (2018)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Randomized trial of vilazodone versus sertraline in depression: Concerns and comments
por: Praharaj, Samir Kumar
Publicado: (2021)

Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials
por: Shi, Ligen, et al.
Publicado: (2016)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
por: Durgam, Suresh, et al.
Publicado: (2018)

A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder
por: Sinha, Shubhadeep, et al.
Publicado: (2021)

Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study
por: Kadam, Renuka L., et al.
Publicado: (2020)

Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial
por: Clayton, Anita H., et al.
Publicado: (2015)

Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial
por: Citrome, Leslie, et al.
Publicado: (2015)

Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
por: Mathews, Maju, et al.
Publicado: (2015)

Vilazodone-Induced Hyperglycemia: A Case Series
por: Das, Abhipsa, et al.
Publicado: (2020)

The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
por: McIntyre, Roger S
Publicado: (2017)

Crystal structure of vilazodone hydrochloride methanol monosolvate
por: Hu, Xiu-Rong, et al.
Publicado: (2016)

The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter
por: Plenge, Per, et al.
Publicado: (2021)

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials
por: Thase, Michael E., et al.
Publicado: (2017)

Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trials
por: Durgam, Suresh, et al.
Publicado: (2016)

Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials
por: Kornstein, Susan, et al.
Publicado: (2018)

Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature
por: Kelliny, Marc, et al.
Publicado: (2015)

A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression
por: Bathla, Manish, et al.
Publicado: (2020)

Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone
por: Khan, Arif, et al.
Publicado: (2016)

A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up
por: Findling, Robert L., et al.
Publicado: (2020)

Updates in the Pharmacologic Prophylaxis and Treatment of Invasive Candidiasis in the Pediatric and Neonatal Intensive Care Units: Updates in the Pharmacologic Prophylaxis
por: Fly, James Hunter, et al.
Publicado: (2022)

Identification of the Antidepressant Vilazodone as an Inhibitor of Inositol Polyphosphate Multikinase by Structure-Based Drug Repositioning
por: Lee, Boah, et al.
Publicado: (2020)

Treatment of nonpsychotic major depression during pregnancy: patient safety and challenges
por: Epstein, Richard A, et al.
Publicado: (2014)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study
por: Clayton, Anita H., et al.
Publicado: (2017)

Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson’s Disease: An Updated Review
por: Angelopoulou, Efthalia, et al.
Publicado: (2023)

Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats
por: Oosting, Ronald S., et al.
Publicado: (2016)

Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studies
por: Clayton, Anita H, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_iidnqhh9an4uq7a7jkeqmk2ml4